Versartis (NASDAQ:VSAR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.
According to Zacks, “Versartis, Inc. operates as a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 2a clinical trials for the treatment of growth hormone deficiency. Versartis, Inc. is headquartered in Redwood City, California. “
Other equities analysts have also issued reports about the company. Cantor Fitzgerald set a $14.00 price objective on Versartis and gave the stock a “buy” rating in a research note on Friday, October 27th. Bank of America lowered Versartis from a “buy” rating to a “neutral” rating in a research note on Monday, September 25th. Finally, Citigroup lowered Versartis from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $23.00 to $3.00 in a research note on Monday, September 25th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $5.63.
Versartis (NASDAQ:VSAR) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.78). During the same period last year, the company posted ($0.92) earnings per share. research analysts predict that Versartis will post -4.14 EPS for the current fiscal year.
In other news, Director Srinivas Akkaraju purchased 419,700 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were purchased at an average cost of $2.13 per share, for a total transaction of $893,961.00. Following the completion of the purchase, the director now directly owns 14,955 shares of the company’s stock, valued at approximately $31,854.15. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 10.90% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. Tudor Investment Corp ET AL bought a new position in Versartis during the second quarter valued at about $218,000. Numeric Investors LLC bought a new position in Versartis during the second quarter valued at about $246,000. Voya Investment Management LLC increased its stake in Versartis by 26.1% during the second quarter. Voya Investment Management LLC now owns 14,960 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 3,094 shares during the period. Cornerstone Capital Management Holdings LLC. increased its stake in Versartis by 13.6% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 24,714 shares of the biopharmaceutical company’s stock valued at $431,000 after acquiring an additional 2,967 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in Versartis by 4.8% during the second quarter. The Manufacturers Life Insurance Company now owns 26,326 shares of the biopharmaceutical company’s stock valued at $459,000 after acquiring an additional 1,204 shares during the period. Hedge funds and other institutional investors own 49.18% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/21/zacks-investment-research-downgrades-versartis-vsar-to-sell.html.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.